Pure ductal adenocarcinoma of the prostate (dPC) is thought to be found in just 0.4 to 0.8 percent of men who get diagnosed with prostate cancer each year. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: adenocarcinoma, damage, DNA, ductal, homologous, mismatch, prostate, repair, sequencing | Leave a comment »
A newly published paper by an international group of investigators has given us some further insight in to the roles of immunotherapeutic agents in the treatment of at least a subset of men with advanced forms of prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: defect, immunotherapy, mismatch, nivolumab, PD-1, pembrolizumab, repair | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 